Show simple item record

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

dc.contributor.authorVicencio, JMen_US
dc.contributor.authorEvans, Ren_US
dc.contributor.authorGreen, Ren_US
dc.contributor.authorAn, Zen_US
dc.contributor.authorDeng, Jen_US
dc.contributor.authorTreacy, Cen_US
dc.contributor.authorMustapha, Ren_US
dc.contributor.authorMonypenny, Jen_US
dc.contributor.authorCostoya, Cen_US
dc.contributor.authorLawler, Ken_US
dc.contributor.authorNg, Ken_US
dc.contributor.authorDe-Souza, Ken_US
dc.contributor.authorCoban, Oen_US
dc.contributor.authorGomez, Ven_US
dc.contributor.authorClancy, Jen_US
dc.contributor.authorChen, SHen_US
dc.contributor.authorChalk, Aen_US
dc.contributor.authorWong, Fen_US
dc.contributor.authorGordon, Pen_US
dc.contributor.authorSavage, Cen_US
dc.contributor.authorGomes, Cen_US
dc.contributor.authorPan, Ten_US
dc.contributor.authorAlfano, Gen_US
dc.contributor.authorDolcetti, Len_US
dc.contributor.authorChan, JNEen_US
dc.contributor.authorFlores-Borja, Fen_US
dc.contributor.authorBarber, PRen_US
dc.contributor.authorWeitsman, Gen_US
dc.contributor.authorSosnowska, Den_US
dc.contributor.authorCapone, Een_US
dc.contributor.authorIacobelli, Sen_US
dc.contributor.authorHochhauser, Den_US
dc.contributor.authorHartley, JAen_US
dc.contributor.authorParsons, Men_US
dc.contributor.authorArnold, JNen_US
dc.contributor.authorAmeer-Beg, Sen_US
dc.contributor.authorQuezada, SAen_US
dc.contributor.authorYarden, Yen_US
dc.contributor.authorSala, Gen_US
dc.contributor.authorNg, Ten_US
dc.date.accessioned2023-11-21T11:54:55Z
dc.date.available2022-03-01en_US
dc.date.issued2022en_US
dc.identifier.issn2041-4889en_US
dc.identifier.otherARTN 274
dc.identifier.otherARTN 274
dc.identifier.otherARTN 274en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/92108
dc.relation.ispartofCELL DEATH & DISEASEen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.titleOsimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in transen_US
dc.typeArticle
dc.identifier.doi10.1038/s41419-022-04701-3en_US
pubs.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000778609500002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume13en_US


Files in this item

Thumbnail
Name:
Flores-Borja Osimertinib and ...
Size:
4.325Mb
Format:
application/
Description:
Published version
View/Open
Thumbnail
Name:
license_rdf
Size:
914bytes
Format:
application/rdf+xml
View/Open

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States